CN116036162B - 一种治疗多囊卵巢综合征的中药组合物及其应用 - Google Patents
一种治疗多囊卵巢综合征的中药组合物及其应用 Download PDFInfo
- Publication number
- CN116036162B CN116036162B CN202310059725.7A CN202310059725A CN116036162B CN 116036162 B CN116036162 B CN 116036162B CN 202310059725 A CN202310059725 A CN 202310059725A CN 116036162 B CN116036162 B CN 116036162B
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- traditional chinese
- chinese medicine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 206010036049 Polycystic ovaries Diseases 0.000 title description 3
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 23
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 23
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 23
- 244000197580 Poria cocos Species 0.000 claims abstract description 23
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 23
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 22
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 21
- 235000006533 astragalus Nutrition 0.000 claims abstract description 21
- 235000005412 red sage Nutrition 0.000 claims abstract description 21
- 241001061264 Astragalus Species 0.000 claims abstract description 18
- 241000913745 Spatholobus Species 0.000 claims abstract description 18
- 210000004233 talus Anatomy 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 241001092035 Photinia Species 0.000 claims description 14
- 230000007812 deficiency Effects 0.000 claims description 11
- 238000009825 accumulation Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 230000005906 menstruation Effects 0.000 abstract description 9
- 208000004880 Polyuria Diseases 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000035619 diuresis Effects 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 241001092500 Photinia x fraseri Species 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 230000003821 menstrual periods Effects 0.000 abstract description 3
- 206010030113 Oedema Diseases 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 230000000630 rising effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 25
- 241000700159 Rattus Species 0.000 description 22
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000007796 conventional method Methods 0.000 description 13
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 13
- 210000001672 ovary Anatomy 0.000 description 10
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 9
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 229940028334 follicle stimulating hormone Drugs 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102000009151 Luteinizing Hormone Human genes 0.000 description 8
- 108010073521 Luteinizing Hormone Proteins 0.000 description 8
- 229940040129 luteinizing hormone Drugs 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010058823 Ovarian mass Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 201000010066 hyperandrogenism Diseases 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 201000005670 Anovulation Diseases 0.000 description 2
- 206010002659 Anovulatory cycle Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 2
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 231100000552 anovulation Toxicity 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000906579 Actaea cimicifuga Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003243 anti-lipolytic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗多囊卵巢综合征的中药组合物,它是由下列重量份的原料药制成:黄芪20‑40份、丹参9‑21份、茯苓6‑18份、当归3‑15份、汉防己3‑15份、荷叶6‑14份、鸡血藤9‑21份、石楠叶3‑15份。本发明还提供了所述中药组合物的用途。本发明的优点在于:黄芪、丹参共为君药,两药合用益气祛湿、活血通经并进;茯苓、当归共为臣药,茯苓健脾利水渗湿,助黄芪健脾益气之功;当归补血活血调经,增丹参养血活血通经之力;汉防己利水消肿,荷叶清暑利湿、升发清阳,佐助利水渗湿之效,二者共为佐药;鸡血藤、石楠叶共为使药,可引药入肝肾经,以助女子月事来潮。该中药组合物不仅符合君臣佐使的配伍,诸药合用,共奏益气化湿,活血通经之效。
Description
【技术领域】
本发明涉及一种治疗多囊卵巢综合征的中药组合物及其应用,具体地说,是以中草药为原料制成的中成药。
【背景技术】
多囊卵巢综合征(poly cystic ovary syndrome,PCOS)是育龄期妇女常见的一种内分泌代谢异常综合性疾病。主要表现为稀发排卵或无排卵、多毛、肥胖、高雄激素血症、胰岛素抵抗及多囊样卵巢。PCOS在育龄期妇女中发病率为5%~10%,在无排卵的不孕症患者中占50%~70%,而我国育龄期妇女中PCOS的群体发病率已达到5.6%,其远期并发症包括脂肪肝、高血压病、2型糖尿病及心血管疾病等。由于其症状的高度异质性、病因复杂性,其发病机制至今仍不完全清楚。肥胖是PCOS常见的特征表现,流行病学资料显示,约有50%~75%的PCOS患者存在超重或肥胖,且以中心性肥胖(腹型肥胖)居多。现代医学研究显示,PCOS患者肥胖症状的发生与PCOS疾病的发生发展互为因果。PCOS患者体内增多的游离睾酮可增强α-肾上腺素的抗脂肪分解作用,从而导致脂肪积聚;另外,体内大量雄激素时,性激素结合球蛋白表达水平下降,增加的游离雄激素与脂肪组织中的雄激素受体相结合,使脂肪细胞分裂、脂肪生长、甘油三酯(TG)贮藏,而腹部和脏器脂肪的积聚也可进一步导致高雄激素血症的发生,两者相互作用,相互促进以致恶性循环。本方中荷叶现代医学研究发现,荷叶含有荷叶碱、莲碱等多种成分,具有降脂减肥、改善胰岛素抵抗等作用。
祖国医学虽无“多囊卵巢综合征”这一病名,根据其临床表现,可属于“闭经”、“月经后期”、“崩漏”、“不孕”等范畴。现代中医认为PCOS的发病与肾—天癸—冲任—胞宫轴的功能失调有关。本病责之于肾、肝、脾三脏,多由肾气不足,冲任匮乏;脾虚痰湿,脂膜壅塞;或肝郁化热,湿热互结而导致本病的发生。临床可根据其症状、体征和舌脉,可分为肾虚、痰湿阻滞、气虚湿蕴、肝经湿热等证型辩证施治。其中气虚湿蕴PCOS患者主要表现为月经稀发或迟闭、量少色淡,其人多体型肥胖、苔腻脉滑或伴咳喘痰多、肢节酸重等。中医学有“肥人多痰湿”之说,认为脾虚不运,气虚湿蕴是肥胖的根本。痰湿雍阻气机,胞脉阻塞,不能摄精成孕,故婚久不孕,月经后错且量少;痰湿内阻,清阳不升,浊阴不降,故头晕心悸,胸闷泛恶;舌淡、苔白腻,脉滑为痰湿内阻之象。
中国专利文献CN201810754444.2,公开了一种治疗脾虚痰湿型多囊卵巢综合征的药物组合物,该中药是由下述重量配比的原料制成的:由黄芪2g、丹参3g、茯苓2g、陈皮2g、苍术4g、当归3g、川芎1g和甘草1.5g。
中国专利文献CN201910925191.5,公开了一种治疗痰湿阻滞型多囊卵巢综合征的中药组合物,该中药是由下述重量配比的原料制成的:黄芪9-45份、茯苓9-15份、白术9-15份、升麻6-10份、柴胡6-8份、泽泻9-15份、陈皮6-9份、当归9-30份、白芍9-18份、熟地9-30份、皂角刺9-12份、夏枯草9-18份、海藻9-18份、石菖蒲9-18份、桃仁9-12份、红花9-12份、丹参15-30份、补骨脂6-10份、姜半夏9-12份、淫羊藿9-18份。结果证实了该中药组合物具有疗效确切,毒副作用小,成本低廉,便于推广应用的优势。
诸如此类治疗多囊卵巢综合征的中药组合物有很多,但是或多或少都有缺点。例如,药味过多,取材难,价格昂贵;药效不明显,治疗效果差等。因此,亟需一种治疗多囊卵巢综合征效果明显、便于制备的药物。
【发明内容】
本发明的目的是针对现有技术中的不足,提供一种治疗多囊卵巢综合征的中药组合物。
本发明的再一目的是,提供一种上述药物的用途。
为实现上述目的,本发明采取的技术方案是:
一种治疗多囊卵巢综合征的中药组合物,是由下列重量份的原料药制成:黄芪20-40份、丹参9-21份、茯苓6-18份、当归3-15份、汉防己3-15份、荷叶6-14份、鸡血藤9-21份、石楠叶3-15份。
优选地,所述的中药组合物是由以下重量份的原料药制成:黄芪25-35份、丹参12-18份、茯苓9-15份、当归6-12份、汉防己6-12份、荷叶8-12份、鸡血藤12-18份、石楠叶6-12份。
更优选地,所述的中药组合物是由以下重量份的原料药制成:黄芪30份、丹参15份、茯苓12份、当归9份、汉防己9份、荷叶10份、鸡血藤15份、石楠叶9份。
所述的药物的药剂是胶囊、颗粒、片剂、口服液、合剂或糖浆剂。
为实现上述第二个目的,本发明采取的技术方案是:
所述的药物在制备治疗多囊卵巢综合征药物中的应用。
优选地,所述的多囊卵巢综合征为气虚湿蕴型多囊卵巢综合征。
本发明优点在于:
黄芪丹参共为君药,两药合用益气祛湿、活血通经并进;茯苓当归共为臣药,茯苓健脾利水渗湿,助黄芪健脾益气之功;当归补血活血调经,增丹参养血活血通经之力;汉防己利水消肿,荷叶清暑利湿、升发清阳,佐助利水渗湿之效,共为佐药;鸡血藤、石楠叶共为使药,可引药入肝肾经,以助女子月事来潮。该中药组合物不仅符合君臣佐使的配伍,诸药合用,共奏益气化湿,活血通经之效。
【具体实施方式】
下面结合具体实施方式对本发明作详细说明。在阅读了本发明记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1治疗多囊卵巢综合征的中药组合物的制备(一)
黄芪30份、丹参15份、茯苓12份、当归9份、汉防己9份、荷叶10份、鸡血藤15份、石楠叶9份,常规方法煎煮。
实施例2治疗多囊卵巢综合征的中药组合物的制备(二)
黄芪30份、丹参12份、茯苓15份、当归3份、汉防己15份、荷叶10份、鸡血藤12份、石楠叶12份,常规方法煎煮。
实施例3治疗多囊卵巢综合征的中药组合物的制备(三)
黄芪25份、丹参18份、茯苓6份、当归15份、汉防己9份、荷叶8份、鸡血藤18份、石楠叶3份,常规方法煎煮。
实施例4治疗多囊卵巢综合征的中药组合物的制备(四)
黄芪35份、丹参9份、茯苓18份、当归9份、汉防己6份、荷叶12份、鸡血藤9份、石楠叶15份,常规方法煎煮。
实施例5治疗多囊卵巢综合征的中药组合物的制备(五)
黄芪20份、丹参21份、茯苓12份、当归6份、汉防己12份、荷叶6份、鸡血藤21份、石楠叶9份,常规方法煎煮。
实施例6治疗多囊卵巢综合征的中药组合物的制备(六)
黄芪40份、丹参15份、茯苓9份、当归12份、汉防己3份、荷叶14份、鸡血藤15份、石楠叶6份,常规方法煎煮。
实施例7治疗多囊卵巢综合征的中药组合物的制备(七)
黄芪30份、丹参18份、茯苓6份、当归15份、汉防己9份、荷叶8份、鸡血藤18份、石楠叶3份,常规方法煎煮。
实施例8治疗多囊卵巢综合征的中药组合物的制备(八)
黄芪25份、丹参9份、茯苓18份、当归9份、汉防己6份、荷叶12份、鸡血藤9份、石楠叶15份,常规方法煎煮。
实施例9治疗多囊卵巢综合征的中药组合物的制备(九)
黄芪35份、丹参21份、茯苓12份、当归6份、汉防己12份、荷叶6份、鸡血藤21份、石楠叶9份,常规方法煎煮。
实施例10治疗多囊卵巢综合征的中药组合物的制备(十)
黄芪20份、丹参15份、茯苓9份、当归12份、汉防己3份、荷叶14份、鸡血藤15份、石楠叶6份,常规方法煎煮。
实施例11治疗多囊卵巢综合征的中药组合物的制备(十一)
黄芪40份、丹参12份、茯苓15份、当归3份、汉防己15份、荷叶10份、鸡血藤12份、石楠叶12份,常规方法煎煮。
需要说明的是,实施例1-11所述的常规方法煎煮是中药汤剂常规的制作方法,即将所述的原料药加水煎煮成汤剂。
实施例12治疗多囊卵巢综合征的中药组合物片剂/胶囊的制备
取实施例1-11任一所述的药物,加9-11倍量水,煎煮2-3.5小时,滤出药汁。再加9倍量水,煎煮2.5小时,滤出药汁,合并二次煎液,静置,滤取上清液,浓缩,放冷,加浓缩液3倍量酒精,搅拌沉淀过夜。取上清液,浓缩至稠浸膏;加入制药辅料,真空干燥,粉碎制粒,压制成片剂或填充装胶囊。
实施例13治疗多囊卵巢综合征的中药组合物颗粒的制备
取实施例1-11任一所述的药物,加8-10倍量水,煎煮3小时,滤出药汁。再加10倍量水,煎煮2.5小时,滤出药汁,合并二次煎液,静置,滤取上清液,浓缩,放冷,加浓缩液2倍量酒精,搅拌沉淀过夜。取上清液,浓缩至稠浸膏;加适当制药辅料,制粒,干燥,整粒,得20g颗粒,分装10g/袋。
实施例14治疗多囊卵巢综合征的中药组合物合剂/口服液/糖浆剂的制备
取实施例1-11任一所述的药物,加8-11倍量水,煎煮3小时,滤出药汁。再加8倍量水,煎煮3小时,滤出药汁,合并二次煎液,静置,滤取上清液,浓缩,放冷,加浓缩液3.5倍量酒精,搅拌沉淀过夜。取上清液,浓缩至稠浸膏;加适当制药辅料,制成合剂、口服液或糖浆剂。
实施例15动物实验
1.实验材料
1.1动物
40只SPF级SD大鼠,6周龄,体重(180±20)g(由中国科学院上海药物研究所提供,实验动物生产许可证号:SCXK(沪)2020-0005)。所有大鼠分笼饲养,温度20~22℃、湿度50%~60%,正常光照,自由饮水进食。
1.2试剂及药物
睾酮(T)、促卵泡素(FSH)、促黄体生成素(LH)、酶联免疫吸附测定(ELISA)试剂盒(南京建成生物工程研究所);
来曲唑(上海麦克林生化科技有限公司);
多囊方(黄芪30克、丹参15克、茯苓12克、当归9克、汉防己9克、荷叶9克、鸡血藤15克、石楠叶9克),水煎浓缩成1g/ml。
2.实验方法
2.1造模、分组及给药
40只大鼠随机分为空白对照组10只,模型组30只。
模型组:来曲唑按1mg/kg灌胃造模,每天1次,连续21d,造模第16天开始进行阴道涂片检测,当光镜下可见阴道上皮细胞持续角化则表示造模成功。
30只模型组大鼠随机分为:
模型对照组10只:每天予1ml/kg氯化钠溶液灌胃;
低剂量实验组10只:多囊方每天予5.5g/kg;
高剂量实验组10只:多囊方每天予11.0g/kg。
其中空白对照组和模型对照组正常饲养28天。低、高剂量实验组给药28天。
2.2取材
大鼠空腹取腹主动脉血4~8mL,3500r/min,离心15min,取上清液,置入-20℃冰箱冷冻保存待测。抽血称重后采用脊椎脱臼法处死所有大鼠,剖取卵巢,去除周围组织,以生理盐水洗涤后观察卵巢外观形态;以滤纸吸尽卵巢表面液体后称质量;称重后以多聚甲醛固定。将卵巢石蜡组织切片,脱蜡、水化后,行HE染色。
2.3检测指标
(1)大鼠卵巢外观形态比较;
(2)大鼠卵巢组织病理形态学变化;
(3)大鼠体质量、卵巢质量/体质量比;
(4)大鼠血清T、FSH、LH的水平。
2.4统计学方法
采用SPSS 21.0统计软件进行统计学分析。各组大鼠体质量,卵巢质量/体质量比,T、FSH、LH以均数±标准差表示。比较采用T检验及方差分析。P<0.05有统计学意义。
3.实验结果
3.1各组大鼠体质量、卵巢质量/体质量比
与空白对照组比较,模型对照组大鼠体质量及卵巢质量/体质量比明显升高(P<0.05);经治疗后,实验组大鼠和模型对照组比较,大鼠体质量及卵巢质量/体质量比明显下降,高剂量组体质量下降尤其明显(P<0.01),见表1。
表1各组大鼠体质量、卵巢质量/体质量比
注:#和空白对照组比较,p<0.05;△和模型对照组比较,p<0.05。△△和模型对照组比较,p<0.05。
3.2各组大鼠血清T、FSH、LH的水平
与空白对照组比较,模型对照组大鼠T、FSH、LH明显升高(P<0.05);经治疗后,实验组大鼠和模型对照组比较,低剂量组T、FSH下降明显(P<0.05),高剂量组T、FSH、LH均有下降(P<0.05),见表2。
表2各组大鼠血清T、FSH、LH的水平
注:#和空白对照组比较,P<0.05;△和模型对照组比较,P<0.05。
4.结论
多囊方可减轻模型大鼠的体重,改善卵巢组织细胞结构,降低卵巢质量/体质量比、降低模型大鼠雄激素水平,从而改善卵巢功能,帮助恢复正常月经。
实施例16临床试验
1临床资料
1.1病例来源
本课题观察病例均来源于2017年1月到2019年12月就诊与上海中医药大学附属岳阳中西医结合医院内分泌科门诊的PCOS患者。
1.2诊断标准
PCOS诊断标准:必备条件:符合多囊卵巢综合征诊断标准,月经稀发、闭经或不规则子宫出血;同时以下2者至少符合1者:①高雄激素临床表现(面部及胸背痤疮,四肢严重多毛,黑棘皮征)或高雄激素血症(睾酮>0.78ng/ml),②超声表现为卵巢多囊。
肥胖诊断标准:BMI≥25kg/M2。
1.3纳入标准
(1)女性,18~40岁,BMI≥25kg/M2。
(2)符合PCOS诊断标准。
(3)自愿参加并签署知情同意书。
1.4排除标准
(1)三个月内曾接受性激素类药物治疗者。
(2)三个月内曾接受中西减肥药物治疗的患者。
(3)心肌梗死、心力衰竭或不稳定心绞痛患者。
(4)有卒中史者。
(5)肾功能不良,血肌酐大于正常最高值者。
(6)严重肝功能损害,ALT或AST大于或等于3倍正常最高值者。
(7)精神疾病患者。
(8)肿瘤患者。
(9)对试验药物或其中组成成分过敏的患者。
1.5剔除标准
(1)受试者在试验过程中出现了不宜继续进行试验的情况,研究者可以决定该病例退出本试验;
(2)受试者在试验过程中,突然发生某些严重疾病或并发症,需要接受可能会影响试验疗效的治疗,可以退出本试验;
(3)受试者依从性差,接受治疗措施小于80%或大于120%剂量的患者;或根据知情同意书的规定,中途要求退出试验的患者;
(4)试验中失访的病例。
2.分组与方法:
60例患者按照入组顺序,随机分为二甲双胍组、多囊方+二甲双胍组,每组30例。
二甲双胍组:入选者予二甲双胍,每次1.0g,每天2次,治疗12周。
多囊方+二甲双胍组:入选者予二甲双胍,每次1.0g,每天2次;同时加用多囊方(黄芪30g、丹参30g、茯苓15g、当归9g、汉防己9g、荷叶9g、鸡血藤15g、石楠叶9g),中药水煎剂,每天2次,治疗12周。
3.观察指标:
(1)观察月经周期、经量及经色。
(2)观测治疗前后患者体重、胰岛素抵抗指数、睾酮值变化。胰岛素抵抗指数HOMA-IR=[空腹血糖(mmol/L)×空腹胰岛素(μIU/ml)]/22.5。
4.统计学方法
符合正态分布的数值变量采用均值±标准差进行统计描述;不符合正态分布的数值变量采用中位数进行统计描述;分类变量采用率或频数(构成比)进行统计描述。
统计分析将采用SPSS16.0统计分析软件进行分析。所有统计检验均采用双侧检验,P值小于0.05为所检验的差别有显著的统计学意义。治疗前后不同时间点指标的变化采用单个重复测量因素的方差分析;组间同一时间点数值变量的比较采用两个重复测量因素的方差分析;组内自身前后对照比较符合正态分布的采用配对t检验,不能转换成正态的采用Wilcoxon秩和检验。
5.结果
5.1一般资料
60例PCOS患者,随机分为二甲双胍组30例,平均年龄28.10±6.05岁;多囊方+二甲双胍组30例,平均年龄28.70±5.95岁。两组病例治疗前年龄、体重、BMI、HOMA-IR、睾酮(T)等均无统计学差异(P>0.05),具有可比性。观察期间,两组均无脱落。观察期间两组均脱落1例,其余患者均完成随访。
5.2两组治疗前后体重、BMI、HOMA-IR、睾酮比较
两组治疗后,体重、BMI、HOMA-IR均有所改善,其中多囊方+二甲双胍组优于二甲双胍组(P<0.05);多囊方+二甲双胍组尚能降低T水平,优于二甲双胍组(P<0.05)。结果提示提示二甲双胍治疗基础上,加用多囊方,可进一步降低PCOS患者的体重、BMI、HOMA-IR、T,进而可能调节患者月经紊乱,见表3。
表3两组治疗前后体重、BMI、HOMA-IR、睾酮比较
注:#组内治疗前后比较,p<0.05;△组间治疗后比较,p<0.05。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。
Claims (1)
1.一种治疗多囊卵巢综合征的中药组合物在制备治疗气虚湿蕴型多囊卵巢综合征药物中的应用,其特征在于,是由下列重量份的原料药制成:黄芪30份、丹参15份、茯苓12份、当归9份、汉防己9份、荷叶10份、鸡血藤15份、石楠叶9份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310059725.7A CN116036162B (zh) | 2023-01-17 | 2023-01-17 | 一种治疗多囊卵巢综合征的中药组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310059725.7A CN116036162B (zh) | 2023-01-17 | 2023-01-17 | 一种治疗多囊卵巢综合征的中药组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116036162A CN116036162A (zh) | 2023-05-02 |
CN116036162B true CN116036162B (zh) | 2023-11-21 |
Family
ID=86123503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310059725.7A Active CN116036162B (zh) | 2023-01-17 | 2023-01-17 | 一种治疗多囊卵巢综合征的中药组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116036162B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108653434A (zh) * | 2018-07-11 | 2018-10-16 | 贾丽妍 | 一种治疗脾虚痰湿型多囊卵巢综合征的药物组合物 |
-
2023
- 2023-01-17 CN CN202310059725.7A patent/CN116036162B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108653434A (zh) * | 2018-07-11 | 2018-10-16 | 贾丽妍 | 一种治疗脾虚痰湿型多囊卵巢综合征的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN116036162A (zh) | 2023-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103933220B (zh) | 一种治疗更年期综合症的药物 | |
CN102488743B (zh) | 中药组合物、制备方法及中药制剂 | |
CN109528980B (zh) | 一种用于治疗卵巢储备功能下降疾病的中药组合物及其制药应用 | |
CN110013470B (zh) | 肾宝片在制备治疗盆腔炎性疾病后遗症药物中的应用 | |
CN103006989B (zh) | 一种治疗糖尿病肾病的药物组合物 | |
CN105056128B (zh) | 一种治疗慢性萎缩性胃炎及肠化的中药组合物及制备方法和应用 | |
CN1843446A (zh) | 用于治疗月经不调的组合套装药品 | |
CN116036162B (zh) | 一种治疗多囊卵巢综合征的中药组合物及其应用 | |
CN1695730A (zh) | 一种治疗高血脂症的中药组合物及其制备方法 | |
CN105267559A (zh) | 一种治疗糖尿病周围神经病变的药物及其制作方法 | |
CN104225472A (zh) | 一种治疗口腔粘膜病变的中药制剂及制备方法和用途 | |
CN108403919B (zh) | 一种治疗多囊卵巢综合征的中药组合物及其制备方法和应用 | |
CN103800736B (zh) | 一种治疗高血压肾病的药物组合物及其应用 | |
CN109876127B (zh) | 一种养血当归胶囊及其制备方法 | |
CN104027433B (zh) | 一种中药组合物及其制备方法与临床制剂 | |
CN103006891B (zh) | 一种治疗慢性肾功能衰竭的药物组合物 | |
CN113826882A (zh) | 防治糖尿病的膳食营养补充剂及其制备工艺 | |
CN106075361B (zh) | 一种中药组合物及其制备与应用 | |
CN113101330B (zh) | 一种调经组合物及其应用 | |
CN111388584A (zh) | 一种治疗阳痿的组合物及其制备方法 | |
CN115212265B (zh) | 一种治疗多囊卵巢综合征的中成药 | |
CN114432410B (zh) | 一种活血祛瘀膏方及其应用 | |
CN115487260B (zh) | 一种治疗高胆固醇血症或动脉粥样硬化的中药组合物及其应用 | |
CN110898188A (zh) | 一种治疗肾性蛋白尿的药物及其制备方法 | |
CN101628102A (zh) | 一种用于防治脂肪肝的药及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |